gradient master 108 version 5.3 Search Results


90
ATCC 108 klebsiella pneumoniae initial 81
108 Klebsiella Pneumoniae Initial 81, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/108 klebsiella pneumoniae initial 81/product/ATCC
Average 90 stars, based on 1 article reviews
108 klebsiella pneumoniae initial 81 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Miltenyi Biotec anti lyt 2
Anti Lyt 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti lyt 2/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti lyt 2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

95
ATCC agad01000082 1 query8 2a r type ii a vincentii
Agad01000082 1 Query8 2a R Type Ii A Vincentii, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/agad01000082 1 query8 2a r type ii a vincentii/product/ATCC
Average 95 stars, based on 1 article reviews
agad01000082 1 query8 2a r type ii a vincentii - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

94
ATCC 108 atcc 14718 m extorquens 2 4
108 Atcc 14718 M Extorquens 2 4, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/108 atcc 14718 m extorquens 2 4/product/ATCC
Average 94 stars, based on 1 article reviews
108 atcc 14718 m extorquens 2 4 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

93
ATCC 108 dsm 18207 m oryzae 9 2
108 Dsm 18207 M Oryzae 9 2, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/108 dsm 18207 m oryzae 9 2/product/ATCC
Average 93 stars, based on 1 article reviews
108 dsm 18207 m oryzae 9 2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

99
Thermo Fisher albumin microbubbles
Albumin Microbubbles, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/albumin microbubbles/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
albumin microbubbles - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

94
ATCC l reuteri atcc 53 608
L Reuteri Atcc 53 608, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/l reuteri atcc 53 608/product/ATCC
Average 94 stars, based on 1 article reviews
l reuteri atcc 53 608 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Schattauer GmbH thrombosis and haemostasis
Thrombosis And Haemostasis, supplied by Schattauer GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/thrombosis and haemostasis/product/Schattauer GmbH
Average 90 stars, based on 1 article reviews
thrombosis and haemostasis - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

92
ATCC nt 116 71 nt 110 59 nt 108 53 nt
Nt 116 71 Nt 110 59 Nt 108 53 Nt, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nt 116 71 nt 110 59 nt 108 53 nt/product/ATCC
Average 92 stars, based on 1 article reviews
nt 116 71 nt 110 59 nt 108 53 nt - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

90
HORIBA Ltd so2 emission (horiba)
So2 Emission (Horiba), supplied by HORIBA Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/so2 emission (horiba)/product/HORIBA Ltd
Average 90 stars, based on 1 article reviews
so2 emission (horiba) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Abbott Laboratories champion ada
Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.
Champion Ada, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/champion ada/product/Abbott Laboratories
Average 90 stars, based on 1 article reviews
champion ada - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
ATCC 108 vre initial 34
Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.
108 Vre Initial 34, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/108 vre initial 34/product/ATCC
Average 94 stars, based on 1 article reviews
108 vre initial 34 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

doi: 10.1111/jdv.15174

Figure Lengend Snippet: Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.

Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.

Techniques: Comparison, Immunopeptidomics

Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

doi: 10.1111/jdv.15174

Figure Lengend Snippet: Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.

Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.

Techniques: